BenevolentAI

It's almost time for BioTechX Europe! On 9 October, 10 AM CET, our Co-Founder and Chief Business Officer, Dr Ivan Griffin, will chair 'The benefits of AI within drug discovery' panel discussion. Along with Dr James Malone, our Chief Technology Officer, Ivan will be joined by: 👉 AstraZeneca's Head of AI Strategy & Innovation, Hebe Middlemiss 👉 Merck Group's Director & Head of AI & New Technologies, Daniel Kuhn 👉 Novartis' VP & Global Head of AI & Computational Sciences, Bulent Kiziltan, PhD 👉 QIAGEN's Director of Product Management, Digital Insights Base, Venkatesh Moktali, PhD On 10 October, 11.45 AM CET, Dr James Malone will also deliver a presentation on 'Building trust and explainability in using AI in drug discovery'. Throughout the event, you'll find our expert team at Booth 1116. They're ready to answer your questions about our proprietary pipeline, innovative industry collaborations and validated AI drug discovery technologies. We look forward to seeing you in Basel.

What do we want from AI? In the context of BenevolentAI’s fully explainable language model for target identification, Chief Technology Officer, Dr James Malone, will discuss crucial aspects of AI-driven drug discovery at Lab of the Future today. #LOTFEU2024

Peter Richardson, 1954–2024 Today we commemorate our friend and colleague, Peter Richardson. Peter was one of the founding scientists of BenevolentAI, whose energy, enthusiasm and sheer intellectual firepower helped to shape the company. Perhaps his greatest impact came during the 2020 pandemic, when he identified baricitinib as a potential treatment for COVID-19. This groundbreaking research was published in The Lancet, validated in clinical trials and ultimately led to FDA approval and WHO recommendation. As a direct result of this discovery, baricitinib has been used to treat many hospitalised COVID-19 patients worldwide, and has undoubtedly saved many lives. As a brilliant scientist and leader, and as a kind and thoughtful colleague, Peter had a hugely positive impact on those he worked alongside. He’ll continue to be a source of great inspiration to us all. Our deepest condolences remain with Peter’s family and friends. Further information about Peter’s work, referenced above, is available here: https://lnkd.in/eJA9sPHC

🧠 Amyotrophic Lateral Sclerosis (ALS) is a rare and fatal neurodegenerative disease with limited treatment options. We are progressing our asset BEN-34712 to its next inflection point. 👉 BenevolentAI has a rich drug pipeline of high-potential clinical and preclinical assets. 🚀 To learn more about licensing and commercialisation for specific assets within our pipeline, contact our team: bd@benevolent.ai  

🧠 Glioblastoma (GBM) is an incurable and aggressive brain tumour, accounting for 48.6% of malignant CNS tumours. We are progressing our asset BEN-28010 to its next inflection point. 👉 BenevolentAI has a rich drug pipeline of high-potential clinical and preclinical assets. 🚀 To learn more about licensing and commercialisation for specific assets within our pipeline, contact our team: bd@benevolent.ai

We have a talented team of AI scientists - and our own wet labs - in Cambridge, so it was fantastic to join the Tech Showcase alongside other innovative companies in the Cambridge ecosystem. Thank you to Mishcon de Reya LLP for hosting. #CambridgeTechWeek

❗Ulcerative Colitis & Crohn’s Disease can be debilitating, causing lifelong ulceration and inflammation. We are progressing our asset BEN-8744 to its next inflection point. 👉 BenevolentAI has a rich drug pipeline of high-potential clinical and preclinical assets. 🚀 To learn more about licensing and commercialisation for specific assets within our pipeline, contact our team: bd@benevolent.ai

On 19 September, we will announce our Interim Results for the six months ended 30 June 2024. For details about our planned briefing for analysts, which will be hosted at the offices of Deutsche Numis and online, see: https://lnkd.in/eW5X4TkF

We feature in The Times ‘Future Titans of UK AI’ series by Thomas Saunders, which includes an interview with our CEO, Joerg Moeller, M.D. ‘...[BenevolentAI] can point to real achievements in drug discovery. During the pandemic, it took the start-up only two days to identify baricitinib, a drug originally prescribed to treat rheumatoid arthritis, as a potential treatment for Covid. It soon received emergency approval from regulators in the United States and elsewhere.   Like others in the drug discovery business, it has sought to demystify the black box that often characterises artificial intelligence. “Our focus is on what we are calling explainable AI,” Moeller said. “We want to use it in a very transparent fashion, where we have a track record of what we are doing in terms of the algorithm so that you’re always able to go back and trace back.”’

We were pleased to join Matt Clifford at the Department for Science, Innovation and Technology to share insights for the AI Opportunities Action Plan. It’s vital the UK maximises its AI-driven productivity and investment, builds long-term infrastructure, and leverages its top-tier talent.